IDI [IDI] S-3:

[] [Nason, Yeager, Gerson White & Lioce, P.A. 1645 Palm Beach Lakes Blvd., Suite 1200 West Palm Beach, FL 33401 August 14, 2015 IDI, Inc. 2650 North Military Trail, Suite 300 Boca Raton, Florida 33431 Attention: Derek Dubner Co-Chief Executive Officer IDI, Inc. Registration Statement on Form S-3 Dear Mr. Dubner: In connection with this opinion, we have examined such documents] [INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT LLP Marcum Bernstein & Pinchuk New York, New York August 14, 2015 EX-23.1 3 d81344dex231.htm EX-23.1] [Consent of Independent Auditors We consent to the incorporation by reference in the registration statement on Form S-3 of IDI, Inc. of our report, dated July 8, 2015, relating to our audits of the financial statements of IDI Holdings, LLC as of and for the period from September 22, 2014 (inception) through December 31, 2014, which are included in the]

By | 2016-03-13T15:13:53+00:00 August 14th, 2015|Categories: Chinese Stocks, IDI, Webplus ver|Tags: , , , , , |0 Comments

SORL [SORL Auto Parts] 10-Q:

[] [of the Sarbanes-Oxley Act of 2002 I, Xiao Ping Zhang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of SORL AUTO PARTS, INC.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification of Principal Financial Officer of the Sarbanes-Oxley Act of 2002 I, Zong Yun Zhou, certify that: 1. I have reviewed this quarterly report on Form 10-Q of SORL AUTO PARTS, INC.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Dated: August 14, 2015 Xiao Ping Zhang Chief Executive Officer Zong Yun Zhou Chief Financial Officer (Principal Financial Officer)]

By | 2016-03-18T20:50:04+00:00 August 14th, 2015|Categories: Chinese Stocks, SORL, Webplus ver|Tags: , , , , , |0 Comments

WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)

[The Company’s board of directors, acting upon the unanimous recommendation of the special committee formed by the board of directors (the “Special Committee”), unanimously approved the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Merger, and resolved to recommend that the Company’s shareholders authorize and approve the Merger Agreement and the transactions contemplated by the Merger] [EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among NEW WUXI LIFE SCIENCE LIMITED, WUXI MERGER LIMITED and WUXI PHARMATECH (CAYMAN) INC. Dated as of August 14, 2015 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.01 The Merger 2 Section 1.02 Closing; Closing Date 2 Section 1.03 Effective Time 2 Section 1.04 Effects of the Merger 2 Section] [Form 6-K Description Press release dated August 14, 2015 Agreement and Plan of Merger among WuXi PharmaTech (Cayman) Inc., New WuXi Life Science Limited and WuXi Merger Limited, Dated August 14, 2015 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3 6-K 1 d47457d6k.htm FORM 6-K]

By | 2016-03-24T02:26:21+00:00 August 14th, 2015|Categories: Chinese Stocks, SEC Original, WX|Tags: , , , , , |0 Comments

SFUN [SouFun] 20-F/A:

[] [CERTIFICATION I, Vincent Tianquan Mo, certify that: 1. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;] [CERTIFICATION I, Lanying Guan, certify that: 1. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.]

IDI [IDI] 8-K: (Original Filing)

[IDI, Inc. Reports Second Quarter 2015 Results BOCA RATON, Fla.—August 14, 2015—IDI, Inc. (NYSE MKT: IDI) On July 23, 2015, the Company completed a $10.0 million registered direct offering with an institutional investor, strengthening its cash position. Key highlights for the second quarter of 2015 include: • Rapid development of next-generation data fusion technology, with expected release of idiCORE™ in] [Item 2.02 Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. Item 9.01 Item 9.01 99.1 Press Release, dated August 14, 2015]

By | 2016-03-13T15:15:58+00:00 August 14th, 2015|Categories: Chinese Stocks, IDI, SEC Original|Tags: , , , , , |0 Comments

ACTS [Actions Semiconductor] 6-K: (Original Filing)

[Actions Semiconductor Reports Second Quarter 2015 Results ZHUHAI, China, August 14, 2015 — Actions Semiconductor Co., Ltd. (Nasdaq: ACTS) Commenting on the second quarter results, Dr. Zhenyu Zhou, CEO of Actions Semiconductor said, “Revenue in the second quarter came in at the high end of our expectations and we achieved a meaningful improvement in gross margin. Sales of our multimedia] []

By | 2016-03-19T16:35:59+00:00 August 14th, 2015|Categories: ACTS, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

WX [WuXi PharmaTech (Cayman)] 6-K: The Company’s board of directors, acting upon the

[The Company’s board of directors, acting upon the unanimous recommendation of the special committee formed by the board of directors (the “Special Committee”), unanimously approved the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Merger, and resolved to recommend that the Company’s shareholders authorize and approve the Merger Agreement and the transactions contemplated by the Merger] [EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among NEW WUXI LIFE SCIENCE LIMITED, WUXI MERGER LIMITED and WUXI PHARMATECH (CAYMAN) INC. Dated as of August 14, 2015 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.01 The Merger 2 Section 1.02 Closing; Closing Date 2 Section 1.03 Effective Time 2 Section 1.04 Effects of the Merger 2 Section] [Form 6-K Description Press release dated August 14, 2015 Agreement and Plan of Merger among WuXi PharmaTech (Cayman) Inc., New WuXi Life Science Limited and WuXi Merger Limited, Dated August 14, 2015 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3 6-K 1 d47457d6k.htm FORM 6-K]

By | 2016-03-24T02:27:41+00:00 August 14th, 2015|Categories: Chinese Stocks, Webplus ver, WX|Tags: , , , , , |0 Comments

CPGI [China Shengda Packaging] 10-Q: (Original Filing)

[FORM 10−Q (Mark One) [X] June 30, 2015 For the quarterly period ended: [ ] For the transition period from ____________to _____________ 001-34997 CHINA SHENGDA PACKAGING GROUP INC. Nevada 26-1559574 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) No. 2 Beitang Road People’s Republic of China Xiaoshan Economic and Technological Development Zone (86) 571-82838805 _____________________________________________________ Large] [CERTIFICATIONS I, Daliang Teng, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Shengda Packaging Group Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ken He, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Shengda Packaging Group Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Daliang Teng Chief Executive Officer] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Ken He Chief Financial Officer (Principal Financial Officer)]

By | 2016-03-31T02:46:31+00:00 August 14th, 2015|Categories: Chinese Stocks, CPGI, SEC Original|Tags: , , , , , |0 Comments

IDI [IDI] 8-K: IDI, Inc. Reports Second Quarter 2015 Results BOCA

[IDI, Inc. Reports Second Quarter 2015 Results BOCA RATON, Fla.—August 14, 2015—IDI, Inc. (NYSE MKT: IDI) On July 23, 2015, the Company completed a $10.0 million registered direct offering with an institutional investor, strengthening its cash position. Key highlights for the second quarter of 2015 include: • Rapid development of next-generation data fusion technology, with expected release of idiCORE™ in] [Item 2.02 Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. Item 9.01 Item 9.01 99.1 Press Release, dated August 14, 2015]

By | 2016-03-13T15:16:51+00:00 August 14th, 2015|Categories: Chinese Stocks, IDI, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar